CRVS
Corvus Pharmaceuticals, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-33/100
Last price
10.56
▼ 0.18 (1.68%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
11.20
Prev close
10.74
Day high
10.96
Day low
10.20
Volume
1.44M
Market cap
$888.32M
P/E (TTM)
—
52W range
6.39 – 26.95
Day trading desk
Gap from prior close
+4.28%
Prior close 10.74
VWAP
10.44
+1.13% from price
Relative volume
1.23×
Normal
Session range
18.04%
10.20 – 12.04
Position in range
20%
Near session low
ATR (14D)
0.74
6.99% of price
Prior day high
11.15
PDH
Prior day low
10.45
PDL
Bid / ask spread
—
Quote not published
Session volume
1.22M
Avg 989.05K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.20%
-12.2%
1M
-26.62%
-27.8%
3M
-34.33%
-38.8%
6M
-26.41%
-44.6%
YTD
+37.14%
+22.9%
1Y
+46.87%
+30.5%
3Y
+623.29%
+541.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CRVS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.95M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 11, 26 | MOORE DAVID SCOTT Director |
BUY | 21.70K | $250.24K | Direct |
| May 18, 26 | MILLER RICHARD A Chief Executive Officer |
BUY | 6.93K | $83.45K | Indirect |
| Jun 27, 25 | ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 1.18M | $4.89M | Indirect |
| Jun 27, 25 | THOMPSON PETER A Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 1.18M | $4.89M | Indirect |
| Jun 27, 25 | ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 1.40M | $4.89M | Indirect |
| Jun 27, 25 | THOMPSON PETER A Director and Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 1.40M | $4.89M | Indirect |
| Jun 4, 25 | JONES WILLIAM BENTON Officer |
CONVERSION | 19.36K | $67.75K | Direct |
| May 7, 25 | MILLER RICHARD A Chief Executive Officer |
CONVERSION | 559.07K | $1.96M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
JONES WILLIAM BENTON |
Officer | 173.13K | Conversion of Exercise of derivative security |
MILLER RICHARD A |
Chief Executive Officer | — | Purchase |
MOORE DAVID SCOTT |
Director | 21.70K | Purchase |
ORBIMED ADVISORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
THOMPSON PETER A |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Fundamentals
Market cap$888.32M
Enterprise value$673.82M
Revenue (TTM)—
Gross profit—
EBITDA$-56.85M
Net income$-54.13M
EPS (TTM)$-0.62
Free cash flow$-27.40M
Total cash$215.23M
Total debt$728.00K
Book value / share$2.68
Shares outstanding84.12M
Float72.79M
Short % of float23.21%
Dividend yield0.00%
Beta (5Y)1.43
Valuation & profitability ratios
Trailing P/E—
Forward P/E-9.89
PEG ratio—
Price / sales—
Price / book3.94
EV / revenue—
EV / EBITDA-11.85
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-35.43%
Return on assets-21.66%
Debt / equity0.32
Current ratio16.16
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $33.72M | $19.39M | $16.53M | $24.47M | +73.9% |
| Selling, general & admin | $9.25M | $8.16M | $6.88M | $8.10M | +13.3% |
| Total operating expense | $42.97M | $27.55M | $23.41M | $32.56M | +56.0% |
| Operating income | -$42.97M | -$27.55M | -$23.41M | -$32.56M | -56.0% |
| Net interest income | $2.50M | $1.82M | $1.58M | $654.00K | +37.3% |
| Pre-tax income | -$15.28M | -$62.29M | -$27.03M | -$41.31M | +75.5% |
| Net income | -$15.28M | -$62.29M | -$27.03M | -$41.31M | +75.5% |
| Net income to common | -$15.28M | -$62.29M | -$27.03M | -$41.31M | +75.5% |
| Basic EPS | -0.19 | -1.02 | -0.56 | -0.89 | +81.4% |
| Diluted EPS | -0.53 | -1.02 | -0.56 | -0.89 | +48.0% |
| EBIT | -$42.97M | -$27.55M | -$23.41M | -$32.56M | -56.0% |
| EBITDA | -$42.87M | -$27.46M | -$23.26M | -$32.20M | -56.1% |
| Basic shares | 78.96M | 60.99M | 48.03M | 46.55M | +29.5% |
| Diluted shares | 79.74M | 60.99M | 48.03M | 46.55M | +30.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.58M | $8.74M | $12.62M | $13.16M | -47.6% |
| Cash & short-term investments | $56.75M | $51.96M | $27.15M | $42.30M | +9.2% |
| Accounts receivable | $37.00K | $75.00K | $26.00K | $588.00K | -50.7% |
| Total current assets | $58.21M | $54.41M | $27.96M | $43.66M | +7.0% |
| Property, plant & equipment | $1.06M | $1.33M | $1.39M | $2.57M | -20.3% |
| Total assets | $71.12M | $68.91M | $45.55M | $68.24M | +3.2% |
| Total current liabilities | $9.38M | $35.40M | $6.87M | $10.75M | -73.5% |
| Total debt | $937.00K | $1.12M | $1.37M | $2.60M | -16.5% |
| Total liabilities | $9.91M | $36.34M | $6.87M | $12.13M | -72.7% |
| Retained earnings | -$412.29M | -$397.01M | -$334.72M | -$307.69M | -3.8% |
| Shareholder equity | $61.20M | $32.57M | $38.68M | $56.12M | +87.9% |
| Working capital | $48.83M | $19.00M | $21.09M | $32.91M | +157.0% |
| Net tangible assets | $61.20M | $32.57M | $38.68M | $56.12M | +87.9% |
| Shares issued | 74.70M | 67.90M | 49.04M | 46.55M | +10.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$15.28M | -$62.29M | -$27.03M | -$41.31M | — | +75.5% |
| Depreciation & amortisation | $105.00K | $85.00K | $151.00K | $367.00K | — | +23.5% |
| Stock-based compensation | $5.33M | $3.00M | $2.15M | $2.69M | — | +77.5% |
| Change in working capital | $3.58M | -$1.65M | -$3.59M | $1.41M | — | +317.3% |
| Operating cash flow | -$32.80M | -$25.42M | -$23.93M | -$27.02M | — | -29.0% |
| Capital expenditure | -$174.00K | — | -$34.00K | -$269.00K | -$5.00K | — |
| Investing cash flow | -$7.80M | -$27.48M | $15.54M | -$23.28M | — | +71.6% |
| Financing cash flow | $36.43M | $49.03M | $7.86M | $0 | — | -25.7% |
| Free cash flow | -$32.97M | -$25.42M | -$23.97M | -$27.29M | — | -29.7% |
| End cash position | $4.58M | $8.74M | $12.62M | $13.16M | — | -47.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $15.96M | $11.18M | $9.94M | $8.45M | $7.87M | +42.9% |
| Selling, general & admin | $3.33M | $3.70M | $2.28M | $2.12M | $2.39M | -10.0% |
| Total operating expense | $19.30M | $14.88M | $12.22M | $10.57M | $10.26M | +29.7% |
| Operating income | -$19.30M | -$14.88M | -$12.22M | -$10.57M | -$10.26M | -29.7% |
| Net interest income | $2.05M | $1.78M | $603.00K | $738.00K | $639.00K | +14.7% |
| Pre-tax income | -$17.96M | -$13.69M | -$12.32M | -$10.16M | -$8.00M | -31.2% |
| Net income | -$17.96M | -$13.69M | -$12.32M | -$10.16M | -$8.00M | -31.2% |
| Net income to common | -$17.96M | -$13.69M | -$12.32M | -$10.16M | -$8.00M | -31.2% |
| Basic EPS | -0.19 | -0.15 | -0.15 | -0.12 | -0.10 | -26.7% |
| Diluted EPS | -0.19 | -0.15 | -0.15 | -0.12 | -0.10 | -26.7% |
| EBIT | -$19.30M | -$14.88M | -$12.22M | -$10.57M | -$10.26M | -29.7% |
| EBITDA | -$19.26M | -$14.85M | -$12.19M | -$10.54M | -$10.23M | -29.7% |
| Basic shares | 92.37M | 90.00M | 82.96M | 82.84M | 77.77M | +2.6% |
| Diluted shares | 92.37M | 90.00M | 82.96M | 82.84M | 77.77M | +2.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.91M | $40.10M | $4.58M | $2.87M | $14.69M | -52.9% |
| Cash & short-term investments | $215.23M | $236.71M | $56.75M | $65.69M | $74.41M | -9.1% |
| Accounts receivable | $6.00K | $43.00K | $37.00K | $32.00K | $86.00K | -86.0% |
| Total current assets | $220.97M | $239.95M | $58.21M | $66.94M | $75.78M | -7.9% |
| Property, plant & equipment | $1.49M | $1.03M | $1.06M | $1.15M | $1.26M | +44.1% |
| Total assets | $239.27M | $253.19M | $71.12M | $80.47M | $89.46M | -5.5% |
| Total current liabilities | $13.67M | $12.11M | $9.38M | $8.07M | $8.51M | +12.9% |
| Total debt | $728.00K | $834.00K | $937.00K | $1.01M | $1.08M | -12.7% |
| Total liabilities | $13.95M | $12.52M | $9.91M | $8.71M | $9.23M | +11.4% |
| Retained earnings | -$443.94M | -$425.99M | -$412.29M | -$399.97M | -$389.81M | -4.2% |
| Shareholder equity | $225.33M | $240.68M | $61.20M | $71.77M | $80.23M | -6.4% |
| Working capital | $207.29M | $227.84M | $48.83M | $58.87M | $67.28M | -9.0% |
| Net tangible assets | $225.33M | $240.68M | $61.20M | $71.77M | $80.23M | -6.4% |
| Shares issued | 84.12M | 84.09M | 74.70M | 74.68M | 74.51M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$17.96M | -$13.69M | -$12.32M | -$10.16M | -$8.00M | — | -31.2% |
| Depreciation & amortisation | $34.00K | $29.00K | $26.00K | $28.00K | $29.00K | — | +17.2% |
| Stock-based compensation | $2.61M | $2.65M | $1.57M | $1.25M | $1.26M | — | -1.5% |
| Change in working capital | -$976.00K | $57.00K | $1.08M | -$550.00K | $2.89M | — | -1,812.3% |
| Operating cash flow | -$15.40M | -$10.37M | -$9.19M | -$9.57M | -$5.78M | — | -48.4% |
| Capital expenditure | -$582.00K | -$91.00K | -$25.00K | — | -$113.00K | -$36.00K | -539.6% |
| Investing cash flow | -$5.96M | -$144.85M | $10.88M | -$2.62M | -$20.30M | — | +95.9% |
| Financing cash flow | $166.00K | $190.75M | $20.00K | $360.00K | $35.77M | — | -99.9% |
| Free cash flow | -$15.98M | -$10.46M | -$9.22M | -$9.57M | -$5.89M | — | -52.7% |
| End cash position | $18.91M | $40.10M | $4.58M | $2.87M | $14.69M | — | -52.9% |
Options analytics
Put / call volume
0.48
Call-heavy session
Put / call open interest
0.69
Positioning, not flow
Max pain
18.00
+70.5% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
255
Contracts, this expiry
Put volume
122
Contracts, this expiry
Heaviest call OI
21.00
65 contracts
Heaviest put OI
18.00
51 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.17 | -0.19 | -13.4% |
| Mar 2026 | -0.15 | -0.15 | +2.2% |
| Dec 2025 | -0.13 | -0.15 | -13.2% |
| Sep 2025 | -0.14 | -0.12 | +11.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.21 | 4 | $0 | 0.0% |
| Next quarter | -0.23 | 4 | $0 | 0.0% |
| Current year | -0.78 | 4 | $0 | 0.0% |
| Next year | -1.07 | 4 | $4.55M | 0.0% |
Analyst targets & ownership
Mean target$33.14
High target$42.00
Low target$27.00
Implied upside213.85%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy1 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders3.51%
Held by institutions85.82%
Institutions holding240
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.42
-7.56% from price
SMA 20
12.13
-12.97% from price
SMA 50
13.39
-21.16% from price
SMA 100
13.30
-20.57% from price
SMA 200
14.18
-25.54% from price
EMA 12
11.53
-8.43% from price
EMA 26
12.33
-14.34% from price
EMA 50
12.96
-18.54% from price
RSI (14)
28.4
Oversold
MACD (12,26,9)
-0.80
Hist -0.15
ATR (14)
0.74
6.99% of price
Realised vol 30D
49.5%
Annualised
Bollinger upper
13.86
20, 2σ
Bollinger lower
10.40
20, 2σ
50 / 200 cross
Death
13.39 vs 14.18
Trend bias
Below 200
-25.54%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.41
Less volatile than market
Correlation to SPY
-0.03
Largely independent
Realised vol 30D
49.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-58.6%
Peak to trough
Max drawdown 5Y
-87.8%
Peak to trough
ATR 14
0.74
6.99% of price
Beta (reported)
1.43
5Y monthly, from filing
Short interest
Shares short
17.18M
Prior 19.13M
Change vs prior
-10.2%
Shorts covering
% of float
23.21%
Heavily shorted
% of shares out
20.42%
Against total outstanding
Days to cover
21.5
Crowded exit
Float
72.79M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 17, 26 | Goldman Sachs | INITIATED | — | Buy |
| Mar 13, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Jan 22, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Jan 21, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Jan 21, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jan 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 13, 25 | Barclays | INITIATED | — | Overweight |
| May 20, 25 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 9, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Mar 26, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Mar 26, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 14, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-22
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-05-14
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-24
Corporate Changes & Voting Matters
8-K · 2026-04-23
Offering Registrations
S-3ASR · 2026-03-13
Headlines
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
GlobeNewswire · 6d ago
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?
Simply Wall St. · 12d ago
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
GlobeNewswire · 34d ago
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
GlobeNewswire · 41d ago
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting
Insider Monkey · 51d ago
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ...
GuruFocus.com · 61d ago
Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.